Google
Trusted Resources: News & Events
Latest announcements and gatherings
In Support of Rare Disease Patients Impacted by COVID-19, NORD Launches Premium and Limited Medical Relief Program
United with more than 25 million Americans living with rare diseases, the National Organization for Rare Disorders (NORD®) today launched its COVID-19 Premium & Medical Relief Program to provide vital support to members of the rare disease community affected by the COVID-19 pandemic. The program will assist those with a confirmed rare disease diagnosis who have been directly impacted by the pandemic through a job loss, reduced work hours, furlough, quarantine, etc.
“COVID-19 poses significant threats to the rare disease community, given the susceptibility of those with chronic conditions and the economic challenges that affect their ability to weather this storm. We are hearing from patients who have been furloughed or laid off and desperately need financial support for insurance, COBRA payments, co-pays and medical expenses,” said Pamela Gavin, Chief Strategy Officer for NORD. “Through this new program, we are providing premium and limited medical assistance to rare patients who need it most during this crisis.”
+myBinderRelated Content
-
Greensboro 7-Year-old With Sickle Cell Disease Raises Money for Kids Like himTJ Wilson has sickle cell disease. His t...
-
#RAREis Scholarship FundLiving with a rare disease means managin...
-
Post Traumatic Stress Disorder – WebinarThe Sickle Cell Mental Health Initiative...
-
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™Emmaus Life Sciences, Inc., a leader in ...
-
Qualifying for Social Security Disability With Sickle Cell DiseaseIf you or your child has sickle cell ane...
-
COVID-19 and Sickle Cell Disease-Related Deaths Reported in the United StatesSickle cell disease (SCD) is associated ...
-
Find Patient Assistance With FundFinder, The Patient Access Network (PAN) FoundationAre you tired of monitoring the status o...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.